Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–476 of 476 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 150 Minutes Week Clear all
Terminated Phase 2Phase 3 Interventional

Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer

NCT01348126
View directory record Official record
Conditions
Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Metastatic
Interventions
Docetaxel, Combination of ganetespib and docetaxel
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Tucson, Arizona • Santa Monica, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Oct 13, 2026, 7:06 PM EDT
Completed Not applicable Interventional

Project MOVE Bipolar

NCT07767032
View directory record Official record
Conditions
Bipolar Disorder (BD)
Interventions
BA, SHE, HE, CBEX
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 13, 2026, 7:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Physical Activity and Fertility Care Study

NCT04002414
View directory record Official record
Conditions
Infertility, Female
Interventions
Sufficient physical activity, Insufficient physical activity
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 43 Years · Female only
Enrollment
215 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 13, 2026, 7:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease

NCT01559363
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Tesevatinib
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years to 62 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
11
States / cities
Los Angeles, California • Denver, Colorado • Kansas City, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 13, 2026, 7:06 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

NCT03334617
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Danvatirsen, Ceralasertib, Vistusertib, Olaparib, Oleclumab, Trastuzumab deruxtecan, Cediranib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
17
States / cities
Duarte, California • Fullerton, California • La Jolla, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 13, 2026, 7:06 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Inspiring Seniors Towards Exercise Promotion to Protect Cognition

NCT06496425
View directory record Official record
Conditions
Alzheimer Disease, Physical Activity
Interventions
Beat-accentuated, personalized music stimulation (BMS), Strength Training (ST), Aerobic exercise (AE)
Behavioral
Lead sponsor
Emory University
Other
Eligibility
65 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia • Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 13, 2026, 7:06 PM EDT
Completed Phase 3 Interventional Results available

A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)

NCT02187744
View directory record Official record
Conditions
Early Breast Cancer
Interventions
PF-05280014, Taxotere®, Paraplatin®, Trastuzumab-EU
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Fountain Valley, California • Kingwood, Texas • Shenandoah, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 13, 2026, 7:06 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Lifestyle Interventions for Generalized Anxiety Disorder

NCT01644812
View directory record Official record
Conditions
Aerobic Exercise, Stretching
Interventions
Aerobic exercise, Stretching
Behavioral
Lead sponsor
Southern Methodist University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
2
States / cities
Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Oct 13, 2026, 7:06 PM EDT
Recruiting Not applicable Interventional

Does Blood Flow Restriction Training Improve Quadriceps Function After Arthroscopic Knee Surgery?

NCT03096366
View directory record Official record
Conditions
Quadriceps Atrophy, ACL Reconstruction
Interventions
Blood flow restriction, Physical therapy
Device · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
14 Years to 55 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Oct 13, 2026, 7:06 PM EDT
Recruiting Not applicable Interventional

Muscle and Movement With Anti-Obesity Medications

NCT06645470
View directory record Official record
Conditions
Obesity and Overweight
Interventions
Standard Medical Care (SMC), Monitoring Contacts, Aerobic Training, Resistance Training, Nutrition Education
Other · Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 13, 2026, 7:06 PM EDT
Active, not recruiting Not applicable Interventional

Circadian Health Regulation and Optimization for Rejuvenation Outcomes

NCT07203196
View directory record Official record
Conditions
Aging, Healthy, Blood Sugar; High, Blood Sugar (Glucose) Control, Time Restricted Eating, Circadian Dysregulation
Interventions
Circadian Rhythm Optimization
Behavioral
Lead sponsor
Salk Institute for Biological Studies
Other
Eligibility
50 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 13, 2026, 7:06 PM EDT
Active, not recruiting Phase 2 Interventional

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

NCT04743661
View directory record Official record
Conditions
Recurrent Medulloblastoma, Recurrent Ependymoma
Interventions
Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 13, 2026, 7:06 PM EDT
Completed Phase 3 Interventional Results available

Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

NCT00806819
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Nintedanib (BIBF1120), Pemetrexed, B12, dexamethasone (or corticosteroid equivalent), placebo, Folic Acid
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
40
States / cities
Downy, California • Fountain Valley, California • Fullerton, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 13, 2026, 7:06 PM EDT
Completed Phase 3 Interventional

Women's Activity and Lifestyle Study in Connecticut

NCT02107066
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Exercise
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Oct 13, 2026, 7:06 PM EDT
Recruiting Phase 2 Interventional

Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

NCT05296070
View directory record Official record
Conditions
Marginal Zone Lymphoma
Interventions
Loncastuximab tesirine 150 µg/Kg, Loncastuximab tesirine 75µg/Kg
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
4
States / cities
Duarte, California • Miami, Florida • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 13, 2026, 7:06 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A D1 Agonist For Working Memory

NCT02507206
View directory record Official record
Conditions
Schizotypal Personality Disorder, SPD
Interventions
DAR 0-100A, Placebo
Drug
Lead sponsor
Antonia New
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Oct 13, 2026, 7:06 PM EDT
Completed Phase 3 Interventional

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

NCT01887886
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
erlotinib, onartuzumab, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
15
States / cities
Bakersfield, California • Fullerton, California • Long Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 13, 2026, 7:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Supervised and Unsupervised Physical Activity Programs During a Weight Loss Intervention for Adults

NCT02693132
View directory record Official record
Conditions
Obesity
Interventions
Supervised (SUP-PA), Unsupervised (UNSUP-PA), Step-based (STEP)
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 13, 2026, 7:06 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL

NCT01203930
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions
Idelalisib, Rituximab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
65 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
6
States / cities
La Jolla, California • Stanford, California • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 13, 2026, 7:06 PM EDT
Completed Not applicable Interventional

Hormones and Physical Exercise (HOPE) Study

NCT02056067
View directory record Official record
Conditions
Breast Cancer, Arthralgia
Interventions
Exercise, Attention Control (Health Education)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Oct 13, 2026, 7:06 PM EDT